---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Pharmacokinetics"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Pharmacokinetics. Topics: Vector biodistribution after MRI-guided convection-enhanced delivery in non-human primates and rats, Persistent expression and correlation of vector DNA with transgene expression, Vector DNA in cerebrospinal fluid and blood immediately after administration, Shedding of vector DNA in body fluids and feces and its decline by three months, and 7 further topics. 11 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Vector biodistribution after MRI-guided convection-enhanced delivery in non-human primates and rats

> “Widespread vector DNA and miHTT transgene distribution in the brain was found, particularly in areas associated with HD pathology.”
> “Analysis of both NHP and rat brain regions showed high levels of vector DNA and miHTT expression that were sustained over 6 months and were widespread throughout the brain, thereby confirming high transduction of brain regions relevant for HD and subsequent expression of the transgene in those regions.”
> “Dose-related transduction of the target structures was observed in NHP at 6 months following AAV5-miHTT administration.”

Source: [Spronck et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908995/)

<a id="topic-2.1.2.6.3-2"></a>

### Persistent expression and correlation of vector DNA with transgene expression

> “AAV5-miHTT achieved persistent high-level expression of vector DNA and miHTT transgene.”
> “Even though miHTT expression did not show a strong dose-dependent effect in the high dose, there was a strong correlation between brain vector DNA and miHTT transgene expression (r = 0.68, p < 0.0001) (Figure 3d).”

Source: [Spronck et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908995/)

<a id="topic-2.1.2.6.3-3"></a>

### Vector DNA in cerebrospinal fluid and blood immediately after administration

> “The levels of vector DNA in the CSF in all AAV5-miHTT-treated NHP were approximately 1 × 1010 gc/mL at 1-h post injection.”
> “These data show that after intrastriatal delivery of AAV5-miHTT the vector is shed into CSF and blood very rapidly, which indicated that initially the vector was able to spread systemically and was not limited to the CNS.”

Source: [Spronck et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908995/)

<a id="topic-2.1.2.6.3-4"></a>

### Shedding of vector DNA in body fluids and feces and its decline by three months

> “One week after dosing, vector DNA was found in blood, plasma, feces, urine, nasal swabs and saliva.”
> “These levels declined at 1 month after dosing and by 3 months after dosing the vector DNA levels were below the limit of detection for plasma, feces, urine and semen.”
> “In feces, urine and semen vector DNA was found at day 7 and 1 months after dosing, but no vector was present after 3 months (data not shown).”

Source: [Spronck et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908995/)

<a id="topic-2.1.2.6.3-5"></a>

### Neutralizing antibodies to the vector capsid six months after dosing

> “As would be expected, NAb to AAV5 were present in the blood plasma of both NHP and rats treated with AAV5-miHTT 6 months after dosing (data not shown).”

Source: [Spronck et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908995/)

<a id="topic-2.1.2.6.3-6"></a>

### Dose-dependent vector distribution in the transgenic minipig brain

> “We detected widespread dose-dependent distribution of AAV5-miHTT throughout the tgHD minipig brain that correlated with the engineered microRNA expression.”
> “Although both doses of AAV5-miHTT resulted in a local transduction and subsequently HTT mRNA and huntingtin protein lowering, the highest dose of AAV5-miHTT resulted in vector DNA and miHTT expression in the cortex, suggesting a dose-dependent viral transport.”

Source: [Evers et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6127509/)

<a id="topic-2.1.2.6.3-7"></a>

### Vector DNA distribution and persistence at 6 and 12 months in minipigs after striatal delivery

> “rAAV5-miHTT (1.2 × 1013 vector genome (VG) copies per brain) was successfully administered into the striatum (bilaterally in caudate and putamen), using age-matched untreated animals as controls.”
> “Widespread brain biodistribution of vector DNA was observed, with the highest concentration in target (striatal) regions, thalamus, and cortical regions.”
> “Vector DNA presence and transgene expression were similar at 6 and 12 months after administration.”

Source: [Vallès et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33827977/)

<a id="topic-2.1.2.6.3-8"></a>

### Extent of brain coverage reported by the sponsor in minipigs

> “Vector DNA distribution and transgene expression in minipig brains demonstrated extensive brain coverage comparable at the interim sacrifice timepoints of 6- and 12-months post administration, leading to significant lowering of mutant huntingtin (mHTT) protein in the brain.”
> “The results confirm the long-term expression (up to two years) of AAV5-delivered microRNAs in non-human primates and provide further support for the potential use of extracellular vesicle-associated microRNAs as novel biomarkers in ongoing clinical trials of gene therapies for neurodegenerative diseases, including AMT-130.”

Source: [uniQure press release, preclinical publications (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-publications-preclinical-data-amt-130)

<a id="topic-2.1.2.6.3-9"></a>

### Vector DNA in striatum, cortex, and cerebellum after striatal injection in mice

> “AAV5 vector DNA was present in a dose-dependent pattern in (A) striatum (P < 0.0001) and (B) cortex (P = 0.0009), and detectable in high dose-treated animals in (C) cerebellum (P = 0.0326).”
> “In striatum (the region of direct AAV5-miHTT injection), AAV5 vector DNA was detected in a dose-dependent pattern (P < 0.0001), with 9.6 × 105 and 4.3 × 107 AAV5 genome copies per μg total DNA measured in low and high dose-treated mice, respectively (Fig. 2A).”

Source: [Thomson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10232253/)

<a id="topic-2.1.2.6.3-10"></a>

### Distribution to the hippocampus and cortex and transduction of neurons, astrocytes, and microglia

> “AAV5-GFP showed broad distribution at all time points evaluated and could clearly be observed in the striatum (site of injection), the hippocampus and deeper layers of the cortex at 7 months post-injection (Figure 2A).”
> “We qualitatively observed co-localization of GFP with NeuN (Figure 2B), DARPP-32 (Figure 2C), GFAP (Figure 2D) and Iba1 (Figure 2E) demonstrating transduction of neurons, striatal medium spiny neurons, astrocytes and microglia, respectively.”

Source: [Caron et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7145682/)

<a id="topic-2.1.2.6.3-11"></a>

### Persistence in the brain and vector shedding as registry outcome measures

| Outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “Duration of persistence of AMT-130 in the brain” | “Change over time in levels of AMT-130-derived Vector DNA Expression in the Cerebrospinal Fluid (CSF)” | “Collected for duration of study through month 72 (Cohorts 1 & 2) and through month 16 (Cohorts 3 & 4)” |

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

> “- Change over time in AAV5 vector shedding”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
